Department of Oncology, Taixing people's Hospital Affiliated to Bengbu Medical College, Taixing, China.
Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820977547. doi: 10.1177/1533033820977547.
As a common pathological type of lung cancer, lung adenocarcinoma (LUAD) is mainly treated by surgery, chemotherapy, targeted therapy and radiotherapy. Although a relatively mature treatment system has been established, there are few studies on the microenvironment of LUAD.
The immune and stromal scores of patients from the LUAD cohort in the TCGA database were obtained by using ESTIMATE. The relationship of immune and stromal scores with the clinicopathological characteristics and overall survival of LUAD patients was assessed by R. GO, KEGG and Cox regression analyses were employed to analyze intersecting genes and to identify reliable prognostic markers. The identified genes were also analyzed in the GEPIA database to assess their correlations with survival, and these relationships were verified with the Kaplan-Meier Plotter database.
The immune score was related to the survival time and tumor topography of LUAD patients. There was a significant correlation between stromal score and tumor metastasis. Through multivariate analysis, stage (HR = 1.640, 95% CI = 1.019-2.642, = 0.042) and risk score (HR = 1.036, 95% CI = 1.026-1.046, < 0.001). The genes (ARHGAP15, BTLA, CASS4, CLECL1, FAM129C, STAP1, TESPA1, and S100P) showed credible prognostic value in LUAD patients in TCGA through GEPIA database online analysis and verification in the Kaplan-Meier plotter database.
In the microenvironment of lung adenocarcinoma, the differentially expressed genes screened by immune score and stromal score have certain value in evaluating the survival/prognosis of patients, as well as the invasion and progression of tumors.
肺腺癌（LUAD）作为一种常见的肺癌病理类型，主要通过手术、化疗、靶向治疗和放疗进行治疗。虽然已经建立了相对成熟的治疗体系，但对 LUAD 的微环境研究较少。
从 TCGA 数据库的 LUAD 队列中获取患者的免疫和基质评分，使用 R 评估免疫和基质评分与 LUAD 患者临床病理特征和总生存期的关系。GO、KEGG 和 Cox 回归分析用于分析交集基因，并确定可靠的预后标志物。在 GEPIA 数据库中分析鉴定的基因，评估它们与生存的相关性，并使用 Kaplan-Meier Plotter 数据库验证这些相关性。
免疫评分与 LUAD 患者的生存时间和肿瘤部位有关。基质评分与肿瘤转移有显著相关性。通过多变量分析，分期（HR = 1.640，95%CI = 1.019-2.642，P = 0.042）和风险评分（HR = 1.036，95%CI = 1.026-1.046，P < 0.001）。通过在线 GEPIA 数据库分析和 Kaplan-Meier Plotter 数据库验证，在 TCGA 中，基因（ARHGAP15、BTLA、CASS4、CLECL1、FAM129C、STAP1、TESPA1 和 S100P）在 LUAD 患者中具有可靠的预后价值。
在肺腺癌的微环境中，免疫评分和基质评分筛选出的差异表达基因在评估患者的生存/预后以及肿瘤的侵袭和进展方面具有一定价值。
